Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Number of responders ‐ mild to moderate disease (12 weeks) · IBD patients
IV ferric carboxymaltose probably leads to higher number of responders ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether oral ferric maltol changes number of responders ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · Patients with active Crohn's disease
1 finding from 1 review
QoL · Patients with active Crohn's disease
1 finding from 1 review
Exacerbation of IBD · IBD patients
Etoricoxib showed no clear difference in exacerbation of IBD compared with placebo (low certainty).
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
Health related quality of life at 12 months ‐ SIBDQ ‐ Carrageenan‐free diet · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of responders · IBD patients
Intravenous preparations may leads to higher number of responders compared with oral preparations (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
Fatigue · participants with quiescent IBD
1 finding from 1 review
Withdrawals due to adverse events · participants with quiescent IBD
Electroacupuncture showed no clear difference in withdrawal due to adverse events compared with sham electroacupuncture (low certainty).
1 finding from 1 review
Fatigue · IBD patients
2 findings from 1 review
Quality of life · IBD patients
1 finding from 1 review
Adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found